News & Events
September 2, 2015
Evidentiary Considerations for Integration of Biomarkers in Drug Development SymposiumEvidentiary Considerations for Integration of Biomarkers in Drug Development Symposium On August 21st, the University of Maryland’s Center of Excellence in Regulatory Science and Innovation (M-CERSI), the U.S Food and Drug Administration (FDA), and the Critical Path Institute co-sponsored a symposium titled “Evidentiary Considerations for Integration of Biomarkers in Drug Development” at the University of......
May 6, 2015
Migrating a PRO InstrumentThis webinar provides a detailed description of the process for conducting paper to ePRO migration, mode-specific migrations, usability, feasibility and user acceptance testing as well as case studies of successful migrations. Presenters: Serge Bodart, MSc (Biomedical Systems) Alisandra Johnson, BS (Bracket) PDF version ...
April 13, 2015
Intro to ePRO – Part IIThis webinar provides an overview of current ePRO data collection modes, the mode selection process, key considerations for selecting the most appropriate mode for a study and considerations for migrating an existing PRO instrument to an electronic mode. Presenters: Cindy Howry, MS (YPrime) and Jennifer Ross, MPhilEd (Almac) PDF version ...
January 12, 2015
Intro to ePRO – Part IThis webinar provides an overview of the ePRO Consortium, describes the various modes of PRO data capture, and discusses the trends in the collection of clinical data electronically. Presenters: J. Jason Lundy, PhD (C-Path) and Valdo Arnera, MD (PHT Corp) PDF version ...
November 17, 2014
Dr. Brumfield’s Remarks at Partnering for CuresDr. Martha Brumfield, C-Path’s President and CEO, participated in a panel discussion on November 17, 2014, “Playing nice in the sandbox: Can research-by-consortium accelerate progress against disease?” at “Partnering for Cures”, an annual conference hosted by Faster Cures, a center of the Milken Institute. The panel of consortium leaders discussed how “research-by-consortium” models have been increasingly......